StreetInsider.com News Articles

Form 4 Cue Biopharma, Inc. For: Oct 12 Filed by: Ray Sumita

Wed, 14 Oct 2026 21:40:00 -0400

si-local-file:///var/storage/secattach/20261014/27188248.html

Form 4 Cue Biopharma, Inc. For: Oct 12 Filed by: Meluzio Michael Vincent

Wed, 14 Oct 2026 21:38:00 -0400

si-local-file:///var/storage/secattach/20261014/27188247.html

Form 4 Cue Biopharma, Inc. For: Oct 12 Filed by: Lin Shao-Lee

Wed, 14 Oct 2026 21:37:00 -0400

si-local-file:///var/storage/secattach/20261014/27188246.html

Form 144 Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Tue, 13 Oct 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20261013/27182347.html

Form 144 Cue Biopharma, Inc. Filed by: Ray Sumita

Tue, 13 Oct 2026 20:54:00 -0400

si-local-file:///var/storage/secattach/20261013/27182339.html

Form SCHEDULE 13G/A Cue Biopharma, Inc. Filed by: STROME MARK E

Thu, 08 Oct 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20261008/27163738.html

B.Riley Reiterates Buy Rating on Cue Biopharma (CUE)

Thu, 01 Oct 2026 05:03:43 -0400

B.Riley analyst Mayank Mamtani reiterated a Buy rating and $83.00 price target on Cue Biopharma (NASDAQ: CUE).

The analyst comments "We reiterate our Buy rating and $83 PT on CUE following our 9/29 IgE-mediated diseases KOL event with Drs Dale Umetsu (allergy specialist) of UCSF and John Durkin (dermatologist) of University of New Mexico, which reviewed CUE-221's Ph2 CSU dataset (9/20 CUE-221 topline), Celldex's EMBARQ-CSU Ph3 (9/22 CLDX Ph3 readthrough) and translation into food allergy. Both KOLs viewed the head-to-head comparative data vs. omalizumab as the most informative feature of the dataset, with Dr. Umetsu calling the outperformance surprising given how

Form 8-K Cue Biopharma, Inc. For: Sep 20

Mon, 21 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260921/27083198.html

Cue Biopharma's CUE-221 meets endpoints in phase 2 hives trial

Sun, 20 Sep 2026 06:00:20 -0400

Cue Biopharma (NASDAQ: CUE) announced positive topline results from a Phase 2 clinical trial of CUE-221, an anti-IgE monoclonal antibody, in patients with moderate to severe chronic spontaneous urticaria (CSU), according to a company press release.

The randomized, double-blind, placebo and active comparator-controlled study enrolled 145 participants in China whose condition remained inadequately controlled despite treatment with H1 antihistamines. The trial included a 16-week treatment period followed by a 20-week follow-up.

The primary endpoint — the proportion of patients achieving complete hive resolution (HSS7=0) at week 12 — was met at all three dose levels tested: 4 mg/kg, 2 mg/kg, and 1

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Sun, 20 Sep 2026 06:00:00 -0400

Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile
Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference
Cue Biopharma to host conference call on Monday, September 21, at 8:00 a.m. EDT

BOSTON, Sept. 20, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced positive topline results from the Phase 2 clinical trial of CUE-221 (UB-221) conducted in China by Genesis Life Sciences, a related company of

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Sun, 20 Sep 2026 06:00:00 -0400

Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile
Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference
Cue Biopharma to host conference call on Monday, September 21, at 8:00 a.m. EDT

B.Riley Starts Cue Biopharma (CUE) at Buy

Fri, 18 Sep 2026 04:11:07 -0400

B.Riley analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating and a price target of $83.00.

The analyst comments: “Cue is best understood as a new company. In April 2026 it brought in CEO Shao-Lee Lin, founder of ACELYRIN and formerly CSO at Horizon and head of therapeutic areas at AbbVie, and on the same day in-licensed a new lead drug, CUE 221, rebuilding the investment case around two immunology programs. The near-term opportunity is allergy. CUE-221 is an anti-IgE antibody in the same class as Xolair, the only approved drug in the category, with two

B.Riley Starts Cue Biopharma (CUE) at Buy

Fri, 18 Sep 2026 04:11:07 -0400

B.Riley analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating and a price target of $83.00.

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Garzone Pamela

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998957.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Garzone Pamela

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998957.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Sarraf Pasha

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998964.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Sarraf Pasha

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998964.html

Cue Biopharma (CUE) PT Raised to $66 at Jefferies

Fri, 28 Aug 2026 07:58:44 -0400

Jefferies analyst Maury Raycroft raised the price target on Cue Biopharma (NASDAQ: CUE) to $66.00 (from $4.00) while maintaining a Buy rating.

Form SCHEDULE 13D Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 21 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260821/26962167.html

Form SCHEDULE 13D Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 21 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260821/26962167.html

Form EFFECT Cue Biopharma, Inc.

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958176.html

Form EFFECT Cue Biopharma, Inc.

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958176.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Ray Sumita

Mon, 17 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26939171.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Ray Sumita

Mon, 17 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26939171.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Meluzio Michael Vincent

Mon, 17 Aug 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260817/26939163.html